Mark Kirschbaum

8.6k citations
66 papers · 6.2k · 3 hit papers · h-index 25

Impact in

Papers in

    • Histone Deacetylase Inhibitors Research 27
    • Protein Degradation and Inhibitors 10
    • Acute Myeloid Leukemia Research 23
    • Hematopoietic Stem Cell Transplantation 9
    • Chronic Myeloid Leukemia Treatments 6

Mark Kirschbaum

65 papers receiving 6.1k citations

Mark Kirschbaum's Hit Papers

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma 2009 · 568 citations
5680+9+18Years since publication50010001.5k

Peers

Mark Kirschbaum
Comparison fields: 5 of 98
  • Hematology 3.0k
  • Transplantation 214
  • Genetics 792
  • Immunology 1.4k
  • Oncology 1.8k
Replace Anthony S. Stein with:
Anthony S. Stein United States
Keith Stockerl‐Goldstein United States
Maria Paola Martelli Italy
Martin Gramatzki Germany
Yang O. Huh United States
JH Kersey United States
Amrita Krishnan United States
Javier Briones Spain
Stephen Devereux United Kingdom
María‐Belén Vídriales Spain
Mark Kirschbaum relative to Anthony S. Stein United States Anthony S. Stein's profile →
Citations per field
00.5×1.6×
Anthony S. Stein · 1×
Citations per year

Countries citing papers authored by Mark Kirschbaum

Since Specialization
Citations

This map shows the geographic impact of Mark Kirschbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Kirschbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Kirschbaum more than expected).

Fields of papers citing papers by Mark Kirschbaum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Kirschbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Kirschbaum. The network helps show where Mark Kirschbaum may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Kirschbaum, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Kirschbaum Line = papers co-authored together Mark Kirschbaum links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 66 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
Hit paper breakdown →
19981606
2
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
Hit paper breakdown →
19981469
3
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Hit paper breakdown →
2009568
4 1999462
5 2011362
6 2012202
7 2011158
8 2008119
9 201498
10 201189
11 200681
12 200878
13 200878
14 201562
15 201360
16 201159
17 199850
18 201349
19 199936
20 201935

About Mark Kirschbaum

Mark Kirschbaum is a scholar working on Molecular Biology, Hematology, Pathology and Forensic Medicine, Oncology and Genetics, having authored 66 papers that have together received 6.2k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (27 papers), Acute Myeloid Leukemia Research (23 papers), Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (12 papers), Protein Degradation and Inhibitors (10 papers), Hematopoietic Stem Cell Transplantation (9 papers), Acute Lymphoblastic Leukemia research (8 papers) and Chronic Myeloid Leukemia Treatments (6 papers). The work is most often cited by research in Hematology (3.0k citations), Transplantation (214 citations), Genetics (792 citations), Immunology (1.4k citations) and Oncology (1.8k citations). Mark Kirschbaum has collaborated with scholars based in United States, Australia and Israel. Frequent co-authors include Shimon Slavin, Avraham Amar, Gàbor Varadi, Arnon Nagler, Simcha Samuel, Reuven Or, Gabriel Cividalli, E Naparstek, Ofira Ben‐Tal and Chaim Brautbar. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer Research, Bone Marrow Transplantation and Journal of Cellular Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact